I anticipate RCM Technologies to beat Q3 earnings estimates, driven by sector growth and improved financials. See why we recommend a buy on RCMT stock.
Bristol Myers (BMY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.